Bone histologic response to deferoxamine in aluminum–related bone disease

Bone histologic response to deferoxamine in aluminum–related bone disease. We have examined the changes in bone histology in 28 uremic patients after long–term treatment with the aluminum chelator, deferoxamine. Marked declines in stainable bone–surface aluminum were associated with increases in bone formation rate and osteoblastic osteoid following deferoxamine. The increased bone formation resulted from increases in bone apposition and length of double–tetracycline labels, the latter being highly correlated with the increase in osteoblastic osteoid (r = 0.85). While bone surface aluminum was highly correlated with bone formation rate (r = .69, P